The overview of modern approaches in treatment of triple negative breast cancer
By far the most aggressive subtype of breast cancer is triple negative cancer. The purpose of this review is to analyze current ideas about the pathogenesis, clinical characteristics of different subtypes of triple negative breast cancer, the nature of its metastasis, mechanisms of chemoresistance....
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
QUASAR, LLC
2020-03-01
|
| Series: | Исследования и практика в медицине |
| Subjects: | |
| Online Access: | https://www.rpmj.ru/rpmj/article/view/500 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850025106731958272 |
|---|---|
| author | A. A. Kharitonova I. A. Smirnova M. V. Kiseleva |
| author_facet | A. A. Kharitonova I. A. Smirnova M. V. Kiseleva |
| author_sort | A. A. Kharitonova |
| collection | DOAJ |
| description | By far the most aggressive subtype of breast cancer is triple negative cancer. The purpose of this review is to analyze current ideas about the pathogenesis, clinical characteristics of different subtypes of triple negative breast cancer, the nature of its metastasis, mechanisms of chemoresistance. The review presents the results of modern regimens of drug therapy of triple negative breast cancer according to the publications of domestic and foreign oncologists. On the basis of various clinical studies, the effectiveness of the use of anthracyclines, taxanes in the dose-dense regime, platinum preparations and other chemotherapy drugs for the treatment of triple-negative cancer has been shown. The presented treatment regimens allow to achieve a complete morphological response in 85% of patients, to increase the rates of relapse-free and overall survival, comparable with other subtypes of breast cancer. The review highlights the possibilities of modern targeted drugs-PARP inhibitors, chk1 inhibitors UCN‑01, immunotherapy possibilities for the treatment of this aggressive subtype of breast cancer. |
| format | Article |
| id | doaj-art-55ffa57522cd444bbdd85a08f6f21832 |
| institution | DOAJ |
| issn | 2410-1893 |
| language | Russian |
| publishDate | 2020-03-01 |
| publisher | QUASAR, LLC |
| record_format | Article |
| series | Исследования и практика в медицине |
| spelling | doaj-art-55ffa57522cd444bbdd85a08f6f218322025-08-20T03:00:55ZrusQUASAR, LLCИсследования и практика в медицине2410-18932020-03-0171556510.17709/2409-2231-2020-7-1-6311The overview of modern approaches in treatment of triple negative breast cancerA. A. Kharitonova0I. A. Smirnova1M. V. Kiseleva2A. Tsyb Medical Radiological Research Centre – Branch of the National Medical Radiology Research Centre of the Russian Federation Ministry of HealthA. Tsyb Medical Radiological Research Centre – Branch of the National Medical Radiology Research Centre of the Russian Federation Ministry of HealthA. Tsyb Medical Radiological Research Centre – Branch of the National Medical Radiology Research Centre of the Russian Federation Ministry of HealthBy far the most aggressive subtype of breast cancer is triple negative cancer. The purpose of this review is to analyze current ideas about the pathogenesis, clinical characteristics of different subtypes of triple negative breast cancer, the nature of its metastasis, mechanisms of chemoresistance. The review presents the results of modern regimens of drug therapy of triple negative breast cancer according to the publications of domestic and foreign oncologists. On the basis of various clinical studies, the effectiveness of the use of anthracyclines, taxanes in the dose-dense regime, platinum preparations and other chemotherapy drugs for the treatment of triple-negative cancer has been shown. The presented treatment regimens allow to achieve a complete morphological response in 85% of patients, to increase the rates of relapse-free and overall survival, comparable with other subtypes of breast cancer. The review highlights the possibilities of modern targeted drugs-PARP inhibitors, chk1 inhibitors UCN‑01, immunotherapy possibilities for the treatment of this aggressive subtype of breast cancer.https://www.rpmj.ru/rpmj/article/view/500triple negative breast cancerchemotherapyplatinum drugsanthracyclinesthe dose-dense modebrca associated breast cancertumor stems cells |
| spellingShingle | A. A. Kharitonova I. A. Smirnova M. V. Kiseleva The overview of modern approaches in treatment of triple negative breast cancer Исследования и практика в медицине triple negative breast cancer chemotherapy platinum drugs anthracyclines the dose-dense mode brca associated breast cancer tumor stems cells |
| title | The overview of modern approaches in treatment of triple negative breast cancer |
| title_full | The overview of modern approaches in treatment of triple negative breast cancer |
| title_fullStr | The overview of modern approaches in treatment of triple negative breast cancer |
| title_full_unstemmed | The overview of modern approaches in treatment of triple negative breast cancer |
| title_short | The overview of modern approaches in treatment of triple negative breast cancer |
| title_sort | overview of modern approaches in treatment of triple negative breast cancer |
| topic | triple negative breast cancer chemotherapy platinum drugs anthracyclines the dose-dense mode brca associated breast cancer tumor stems cells |
| url | https://www.rpmj.ru/rpmj/article/view/500 |
| work_keys_str_mv | AT aakharitonova theoverviewofmodernapproachesintreatmentoftriplenegativebreastcancer AT iasmirnova theoverviewofmodernapproachesintreatmentoftriplenegativebreastcancer AT mvkiseleva theoverviewofmodernapproachesintreatmentoftriplenegativebreastcancer AT aakharitonova overviewofmodernapproachesintreatmentoftriplenegativebreastcancer AT iasmirnova overviewofmodernapproachesintreatmentoftriplenegativebreastcancer AT mvkiseleva overviewofmodernapproachesintreatmentoftriplenegativebreastcancer |